Elucida Oncology
1 Deer Park Drive
Suite E
Monmouth Junction
NJ
08852
United States
Website: http://www.elucidaoncology.com/
21 articles about Elucida Oncology
-
Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference
2/15/2024
Elucida Oncology announced that Geno Germano, CEO and President of Elucida Oncology, will present at the Evercore ISI 2024 Emerging Biotech Conference.
-
Elucida Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/27/2023
Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced that Geno Germano, CEO and President of Elucida Oncology, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
-
Elucida Oncology Presents Encouraging Clinical Data from Phase 1/2 Study of ELU001 in Solid Tumors Overexpressing Folate Receptor Alpha at ESMO Congress 2023
10/23/2023
Elucida Oncology announced today that new data have been presented from its recently completed dose escalation/safety phase of its first-in-human Phase 1/2 clinical trial evaluating ELU001, its lead C’Dot drug conjugate (CDC) clinical candidate, at the ESMO Congress 2023 being held in Madrid, Spain.
-
Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
9/11/2023
Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an abstract featuring ELU001, its lead C’Dot Drug Conjugate (CDC) clinical candidate, has been accepted for poster presentation at the ESMO Congress 2023 being held in Madrid, Spain from October 20-24, 2023.
-
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
8/24/2023
Elucida Oncology announced that Ramzi Benamar, a seasoned financial leader with a proven track record in the life sciences industry, has been appointed as Chief Financial Officer, effective September 1, 2023.
-
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
7/20/2023
Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that the first patient has been treated with ELU001, its proprietary folate receptor alpha (FRα)-targeted C’Dot drug conjugate (CDC), in one of three Tumor Group Expansion Cohorts in its Phase 1/2 trial.
-
Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an Anti-Folate Receptor Alpha C’Dot Drug Conjugate
4/20/2023
Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, presented positive initial safety data from Phase 1 dose escalation trial of ELU001 (NCT05001282) in a poster titled “ELU-FRα-1: A Study to Evaluate ELU001, a C’Dot Drug Conjugate, in Patients with Solid Tumors that Overexpress Folate Receptor Alpha (FRα)” (abstract #CT255) at the American Association for Cancer Research (AACR) 2023 Annual Meeting.
-
Elucida Oncology to Present New Clinical and Preclinical Data at the 2023 AACR Annual Meeting
4/11/2023
Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that two abstracts featuring ELU001, its lead C’Dot Drug Conjugate (CDC) clinical candidate, have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, in Orlando, FL.
-
Elucida Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced that management will participate at the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California.
-
Elucida Oncology to Present at the Piper Sandler 34th Annual Healthcare Conference
11/3/2022
Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that management will participate at the Piper Sandler 34th Annual Healthcare Conference, taking place at the Lotte New York Palace on November 29-December 1, 2022.
-
Elucida Oncology to Present at Two Upcoming Conferences in June 2022
6/3/2022
Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced that management will participate at two upcoming conferences in June.
-
Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting
6/1/2022
Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today the Company will present a Trials in Progress poster presentation for the Phase 1/2 Study of ELU001 in patients with advanced, recurrent, or refractory cancers overexpressing Folate-Receptor Alpha (FRα), at the American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference
5/6/2022
Elucida Oncology announced that Geno Germano, CEO and President of Elucida Oncology, will present at the Bank of America 2022 Healthcare Conference in Las Vegas, NV on Tuesday, May 10, at 4:40pm PST.
-
Elucida Oncology to Present at Two Upcoming Scientific Conferences in March
3/3/2022
Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced that Dr. Greg Adams, Chief Scientific Officer of Elucida Oncology, will present at two upcoming industry conferences:.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Elucida Oncology to Present at Two Upcoming Investor Conferences
1/5/2022
Elucida Oncology announced today that Geno Germano, CEO and President of Elucida Oncology, and Ian Somaiya, CFO and CBO of Elucida Oncology, will present at two upcoming virtual investor conferences: The 40th Annual J.P. Morgan Healthcare Conference Date: Tuesday, January 11, 2022 Time: 8:30 a.m. EST.
-
Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones
1/5/2022
Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, provided a corporate update and announced its strategic priorities and anticipated milestones.
-
Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering & Therapeutic Conference
12/15/2021
Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Gregory Adams, Ph.D., Chief Scientific Officer, will be presenting on Thursday, December 16th at 8:30am PST at the Antibody Engineering & Therapeutics Conference.
-
The precision medicine company is developing mutant selective and isoform-specific drugs in non-conventional ways for well-known targets in the oncology and autoimmune spaces.
-
Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer
11/22/2021
Elucida Oncology announced today the appointment of Ian Somaiya as Chief Financial Officer and Chief Business Officer.